Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

  • Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose
  • No safety concerns observed in any age group by an independent Data Monitoring Committee…

Continue Reading